Office of Technology Transfer – University of Michigan

A Specific Antibody for RhoC That Can be Used for Molecular Diagnostics of Human Specimens

Technology #2013

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Sofia D. Merajver
Managed By
Ed Pagani
Associate Director, Health Technologies 734-763-3558
Publications
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.
Am J Pathol, Volume 160. Page 579. 2002

Background

Despite increased awareness of breast cancer and its prevalence, predicting patient outcome is remains difficult. Although the likelihood of metastasis is thought to be linked to the aggressiveness, growth, and size of the primary neoplasm, this is not always the case. There are many small breast cancers with a highly aggressive behavior and discouraging outcome that remain undertreated because there is no marker capable of identifying them. RhoC-GTPase is a member of the Ras-superfamily of small guanosine triphosphatases (GTPases), whose activation leads to assembly of the actin-myosin contractile filaments into focal adhesion complexes that lead to cell polarity and facilitate motility. In addition, overexpression of RhoC has been shown to result in a highly motile and invasive phenotype that recapitulates the most lethal form of locally advanced breast cancer, inflammatory breast cancer.

Technology

Researchers at the University of Michigan have designed and produced a novel antibody to the RhoC GTPase protein that is not cross-reactive with any other members of the Rho family. RhoC is expressed in most tissues normally, but is over-expressed in melanoma, and in pancreatic and inflammatory breast cancers. Using this antibody, RhoC was shown to have high specificity in detecting invasive carcinomas with metastatic potential, including in invasive carcinomas smaller than 1 cm.

Applications and Advantages

Applications

  • Diagnostics for invasive carcinomas with metastatic potential

Advantages

  • May be relevant for various types of cancers